Purpose The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of 18 F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG). Methods A comprehensive computer literature search of studies published through 30 June 2011 regarding 18 F-DO-PA PET or PET/computed tomography (PET/CT) in patients with PG was performed in PubMed/MEDLINE, Embase and Scopus databases. Pooled sensitivity and specificity of 18 F-DOPA PET or PET/CT in patients with PG on a per patient-and on a per lesion-based analysis were calculated. The area under the receiver-operating characteristic (ROC) curve was calculated to measure the accuracy of 18 F-DOPA PET or PET/CT in patients with PG. Furthermore, a subanalysis taking into account the different genetic mutations in PG patients was also performed. Results Eleven studies comprising 275 patients with suspected PG were included in this meta-analysis. The pooled sensitivity of 18 F-DOPA PET and PET/CT in detecting PG was 91% [95% confidence interval (CI) 87-94%] on a per patient-based analysis and 79% (95% CI 76-81%) on a per lesion-based analysis. The pooled specificity of 18 F-DOPA PET and PET/CT in detecting PG was 95% (95% CI 86-99%) on a per patient-based analysis and 95% (95% CI 84-99%) on a per lesion-based analysis. The area under the ROC curve was 0.95 on a per patient-and 0.94 on a per lesion-based analysis. Heterogeneity between the studies about sensitivity of 18 F-DOPA PET or PET/CT was found. A significant increase in sensitivity of 18 F-DOPA PET or PET/CT was observed when a sub-analysis excluding patients with succinate dehydrogenase subunit B (SDHB) gene mutations was performed. Conclusion In patients with suspected PG 18 F-DOPA PET or PET/CT demonstrated high sensitivity and specificity. 
Introduction
Paragangliomas (PG) are rare neuroendocrine tumours arising from chromaffin cells of the sympathetic and parasympathetic paraganglia located from the base of the skull to the urinary bladder. Catecholamine-secreting PG arising from the chromaffin cells of the adrenal medulla are referred to as phaeochromocytomas, whereas sympathetic PG arising outside the adrenals are referred to as extra-adrenal PG [1] . A large tumour size or capsular invasion may indicate malignancy; however, the only reliable evidence of malignancy is the presence of local tumour invasion and/or metastatic spread to distal sites, generally bone, liver and lung or clearly identifiable lymph nodes [2, 3] .
Functional imaging methods are useful to provide accurate staging and extent of the disease in patients with PG. The information obtained by the combination of conventional and functional imaging methods may influence the management of these patients, especially in malignant and multifocal forms [4, 5] .
Recently, the use of positron emission tomography (PET) imaging in these tumours has been growing rapidly and different positron-emitting radiopharmaceuticals (with different uptake mechanisms) have been developed [4, 5] . In particular, 18 F-dihydroxyphenylalanine (DOPA) has been proposed as a useful radiopharmaceutical for the imaging of catecholamine-secreting tumours [6] . DOPA enters the cells through the large amino acid transporter 2; then it is converted by aromatic amino acid decarboxylase to dopamine and transported into storage granules by vesicular monoamine transporter [7] [8] [9] .
Several single-centre studies have evaluated 18 F-DOPA PET or PET/computed tomography (PET/CT) in patients with suspected PG, reporting different values of sensitivity and specificity; the purpose of our study is to systematically review and conduct a meta-analysis of published data on the diagnostic performance of 18 F-DOPA PET or PET/CT in patients with PG.
Materials and methods

Search strategy
A comprehensive computer literature search of the PubMed/ MEDLINE, Embase and Scopus databases was conducted to find relevant published articles on the diagnostic performance of 18 F-DOPA PET and PET/CT in patients with PG. We used a search algorithm that was based on a combination of the terms: (a) "DOPA" OR "dihydroxyphenylalanine" AND (b) "PET" OR "positron emission tomography" AND (c) "paraganglioma" OR "pheochromocytoma" OR "adrenal". No beginning date limit was used; the search was updated until 30 June 2011. No language restriction was used. To expand our search, references of the retrieved articles were also screened for additional studies.
Study selection
Studies or subsets in studies investigating the diagnostic performance of 18 F-DOPA PET or PET/CT in patients with PG were eligible for inclusion. The exclusion criteria were: (a) articles not within the field of interest of this review; (b) review articles, editorials or letters, comments, conference proceedings; (c) case reports or small case series; (d) overlap in patient data (duplicate publication; in such cases the most complete article was included); and (e) insufficient data to reassess sensitivity or specificity from individual studies.
Three researchers (GT, FC and PC) independently reviewed the titles and abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned above. Articles were rejected if they were clearly ineligible. The same three researchers then independently reviewed the full-text version of the remaining articles to determine their eligibility for inclusion. Disagreements were resolved in a consensus meeting.
Data extraction
For each included study, information was collected concerning basic study (authors, year of publication, country of origin), patient characteristics (mean age, sex, number of patients with PG, number of patients with genetic mutations) and technical aspects (device used, radiopharmaceutical injected dose, time between 18 F-DOPA injection and image acquisition, carbidopa pretreatment, image analysis, applied reference standard). For each study the number of true-positive, false-positive, true-negative and falsenegative findings for 18 F-DOPA PET or PET/CT in the diagnosis of PG was recorded on a per patient-and on a per lesion-based analysis.
Quality assessment
Three independent reviewers (CdW, MRG and FDN) evaluated the methodology of the selected studies using the Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS) [10] . This 14-item tool is composed of 5 items related to verification bias (items 3, 4, 5, 6 and 7), 3 items related to review bias (items 10, 11 and 12), 2 items related to generalizability and context and spectrum bias (items 1 and 2) and 4 items related to reporting (items 8, 9, 13 and 14). Reviewers, who were blinded to the purposes of the meta-analysis, recorded a score of "1" for "yes" and "0" for "no" and "unclear" for each of the 14 items; all disagreements were resolved by a consensus. Furthermore, studies were given an A, B, C or D rating according to the quality assessment by Van den Bruel et al. [11] . Studies fulfilling all QUADAS items were rated as A. Studies with no or unclear total verification with the reference standard or with interpretation of the index test unblinded to the results of the reference standard were rated as D, while studies without an independent reference standard, with interpretation of the reference standard unblinded to the results of the index test or with an unduly long period between index and reference tests as C. All other studies were rated as B.
Statistical analysis
Sensitivity and specificity of 18 F-DOPA PET or PET/CT in patients with PG were obtained from individual studies on a per patient-and on a per lesion-based analysis.
A random effects model was used for statistical pooling of the data in the case of heterogeneity between the studies (p<0.1); if there was no heterogeneity between the studies a fixed effects model for statistical pooling of the data was used. Pooled data were presented with 95% confidence intervals (CI). An I-square statistic was also performed to test for heterogeneity between studies. The area under the receiver-operating characteristic (ROC) curve was calculated to measure the accuracy of 18 F-DOPA PET or PET/CT in patients with PG. Furthermore, in order to study the influence of gene mutations on 18 F-DOPA PET or PET/CT findings, a sub-analysis taking into account the different gene mutations was performed.
Statistical analyses were performed using Meta-DiSc statistical software version 1.4 (Unit of Clinical Biostatistics, Ramón y Cajal Hospital, Madrid, Spain) [12] .
Results
Literature search
The comprehensive computer literature search from PubMed/ MEDLINE, Embase and Scopus databases revealed 63 articles. Reviewing titles and abstracts, 42 articles were excluded: 25 because they were not within the field of interest of this review and 17 because they were reviews or editorials.
Twenty-one articles were selected and retrieved in fulltext version; no additional study was found by screening the references of these articles. From these 21 articles potentially eligible for inclusion, after reviewing the full-text article, 6 articles were excluded as case reports or small case series [13] [14] [15] [16] [17] [18] , 1 due to data overlap [19] and 3 due to insufficient data to calculate sensitivity or specificity of 18 F-DOPA PET [20] [21] [22] .
Finally, 11 studies, comprising a total sample size of 275 patients with suspected PG, met all inclusion and exclusion criteria, and they were included in our meta-analysis [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (Fig. 1) . The characteristics of the included studies are presented in Tables 1 and 2 . Quality assessment Table 3 shows the results of the quality assessment of included studies. Studies scored between 7 and 13 with a median score of 9 (interquartile range 2). Most of the studies (six studies 54.5%), including those with larger study populations, scored between 8 and 9; four studies (36.4%) scored 10 or more, whereas only one study [32] achieved a score of 7. In this last study it was unclear if the index test and the reference standard were interpreted under blinded conditions (items 10 and 11) and if all uninterpretable/intermediate results were reported (item 13). Furthermore, patients did not receive the same reference standard regardless of the index test result, and the reference standard was not independent from the index test (items 6 and 7). Moreover, methodology of the reference standard was not likely to correctly classify the target condition (item 3) and was not described in sufficient detail (item 9). Anyway, also in the study by Hoegerle et al. [23] , which achieved the highest score, the reference standard was not likely to correctly classify PG (item 3).
As far as the items are concerned, a brief summary of the most important weaknesses is described. All study populations included patients with suspected or known PG (item 1); anyway, selection criteria (item 2) were clearly described only in six studies (54.5%). Only three studies (27.3%) used histological verification in all patients as the reference standard (item 3); among the remaining eight studies, six used it only when feasible. In three cases (27.3%) it was not possible to be sure that patients did not develop new lesions during the time elapsed from index test to reference standard. In none of the items from 5 to 9 were unclear results observed, but the quality was particularly poor for items 6 and 9. Only in five studies (45.5%) did patients receive the same reference standard regardless of the index test result (item 6), and only in three studies (27.3%) was the execution of the reference standard (which was composite in most cases) described in sufficient detail (item 9). For items 10 and 11 (blindness of index test and reference test, respectively) there was the higher uncertainty: for both items, in four studies (36.4%) it was unclear whether the tests were executed under blind conditions or not. As far as withdrawals are concerned, it should be noted that in most studies no withdrawals were observed (item 14).
Finally, none of the studies achieved an A rating, while two (18.2%) received a B rating and four (36.4%) got a C; all other studies received a D rating.
Diagnostic performance
The diagnostic performance results of 18 F-DOPA PET or PET/CT in the 11 included studies are presented in Figs. 2, 3, 4, 5 and 6. The sensitivity of 18 F-DOPA PET or PET/CT calculated on a per patient-and per lesion-based analysis ranged from 77 to 100% and from 54 to 100%, with pooled estimates of 91% (95% CI 87-94%) and 79% (95% CI 76-81%), respectively (Figs. 2 and 3) . The included studies were statistically heterogeneous in their estimates of sensitivity on a per patient-(I-square 57.3%) and on a per lesionbased analysis (I-square 96.8%).
The specificity of 18 F-DOPA PET and PET/CT calculated on a per patient-and per lesion-based analysis ranged from 75 to 100% and from 67 to 100%, with pooled estimates of 95% (95% CI 86-99%) and 95% (95% CI 84-99%), respectively (Figs. 4 and 5) . The included studies were statistically homogeneous in their estimates of specificity on a per patient-(I-square 0%) and on a per lesion-based analysis (Isquare 0%).
The area under the ROC curve was 0.95 on a per patientand 0.94 on a per lesion-based analysis (Fig. 6) .
The sub-analysis performed taking into account the different genetic mutations showed a significant difference compared to the previously reported findings only when PG patients with succinate dehydrogenase subunit B (SDHB) mutations were excluded from the meta-analysis. In this setting, a relevant increase of pooled sensitivity of 18 F-DOPA PET and PET/CT was found: excluding patients with SDHB mutations the pooled sensitivities were 95% (95% CI 91-98%) and 91% (95% CI 89-93%) on a per patient-and on a per lesion-based analysis, respectively. Furthermore, excluding patients with SDHB mutations, the studies were statistically homogeneous (I-square <25%), and an increase in diagnostic accuracy of 18 F-DOPA PET and PET/CT was also observed (ROC curve was 0.97 on a per patient-and on a per lesion-based analysis).
Discussion
To the best of our knowledge, this meta-analysis is the first to evaluate the diagnostic performance of 18 F-DOPA PET or PET/CT in patients with PG. Several single-centre studies have used 18 F-DOPA PET or PET/CT in patients with suspected PG reporting different values of sensitivity and specificity [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . However, many of these studies have limited power, analysing only relatively small numbers of patients. In order to derive more robust estimates of the diagnostic performance of 18 F-DOPA PET or PET/CT in patients with PG we pooled published studies. A systematic review process was adopted in ascertaining studies, thereby avoiding selection bias. All of the studies included in the review were shown to be of moderate quality according to QUADAS [11] . Anyway, this tool has some limits because it is not supposed to be meant as a scale. In fact, items do have different relevance in the assessment of the quality: a study achieving a very high score, having fulfilled almost all items, could still have a debatable quality if it does not meet one of the most important items, such as the use of the same reference standard in all patients. This clearly arises from the rating of studies according to Van den Bruel et al. [12] . In fact, it is noteworthy to observe that none of the studies achieved an A rating, and nine (81.8%) of the studies had the lowest rating of C and D. Another drawback of the QUADAS is that it does not take into consideration the sample size which is responsible for the precision of the study and its validity too. On the other hand, it is important to remember that the low quality could also be due to the limitations in carrying out these kinds of studies in the real clinical setting, where it might be difficult to confirm the final diagnosis in all patients.
Pooled results of our meta-analysis indicate that 18 F-DOPA PET and PET/CT demonstrate high sensitivity (91%) and high specificity (95%) on a per patient-based 
The QUADAS tool items:
1. Was the spectrum of patients representative of the patients who will receive the test in practice?
2. Were selection criteria clearly described?
3. Is the reference standard likely to correctly classify the target condition?
4. Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests?
5. Did the whole sample or a random selection of the sample receive verification using a reference standard of diagnosis?
6. Did patients receive the same reference standard regardless of the index test result?
7. Was the reference standard independent of the index test (i.e. the index test did not form part of the reference standard)?
8. Was the execution of the index test described in sufficient detail to permit replication of the test?
9. Was the execution of the reference standard described in sufficient detail to permit its replication? analysis and good sensitivity (79%) and high specificity (95%) on a per lesion-based analysis. Furthermore, the area under the ROC curve (0.95 on a per patient-and 0.94 on a per lesion-based analysis) demonstrates that 18 F-DOPA PET and PET/CT are accurate methods for diagnosis of PG.
Nevertheless, possible sources of false-negative results of these functional imaging methods should be kept in mind; they could be related to several factors such as the small size of the lesion, location of the tumour near organs with high physiological 18 F-DOPA uptake (such as the pancreas, biliary and urinary systems) or loss of 18 F-DOPA uptake due to tumour dedifferentiation. Genetic factors may also affect the 18 F-DOPA uptake in PG; SDHB gene mutations may result in extra-adrenal PG for which 18 F-DOPA PET shows a lower sensitivity than for non-SDHB-related lesions [29] . It is possible that the high pooled sensitivity of 18 F-DOPA PET and PET/CT observed in our analysis is related to the small number of patients with SDHB gene mutations enrolled in most of the studies ( Table 1 ), except that of Timmers et al. [29] . In fact, a significant increase in sensitivity of 18 F-DOPA PET or PET/CT was observed when a sub-analysis excluding patients with SDHB gene mutations was performed.
The high specificity of F-DOPA PET [29] ; finally, Luster et al. described an adrenal mass with a mildly intense 18 F-DOPA uptake, but clinical follow-up revealed no evidence of phaeochromocytoma [30] .
The included studies were statistically heterogeneous in their estimates of sensitivity. This heterogeneity is likely to arise through diversity in methodological aspects between different studies (Tables 2 and 3 ). For example, some authors F-DOPA PET and PET/CT ranged from 75 to 100%, with a pooled estimate of 95% (95% CI 86-99%). The included studies were statistically homogeneous in their estimates of specificity (I-square 0%) used carbidopa pretreatment before 18 F-DOPA PET examination; this drug, decreasing decarboxylation and subsequent renal clearance of DOPA, may be used to increase the tumour to background uptake ratio; nevertheless, carbidopa pretreatment should have a low influence on the number of PG lesions depicted by 18 F-DOPA PET, because these tumours usually have high 18 F-DOPA uptake [5, 18] . The baseline differences among the patients in the included studies (Table 1) may have contributed to the observed heterogeneity of the results too. However, such variability was accounted for in a random effects model.
Hybrid PET/CT imaging is usually superior compared to PET alone concerning the diagnostic accuracy for tumour imaging; a possible advantage of PET/CT versus PET alone has not been evaluated in our analysis because the numbers are too small to find a significant difference. Furthermore, some studies performed both PET and PET/CT and separate data could not be retrieved.
A limitation of our analysis is the lack of the calculation of pooled sensitivity and specificity of 18 F-DOPA PET or PET/CT in different forms of PG, for example adrenal vs extra-adrenal, sympathetic vs parasympathetic, functioning vs non-functioning, inherited vs sporadic and metastatic vs non-metastatic tumours; in fact, the frequent mixing of these forms of PG in the patient population of the included studies hampered the data extraction and the separate calculation of diagnostic performance of 18 F-DOPA PET in such groups. Nevertheless, according to the literature, 18 F-DOPA PET and PET/CT seem to be accurate methods in both adrenal [23, 26, 27, 30] and extra-adrenal [24, 25, 31, 32] , sympathetic [23, [26] [27] [28] and parasympathetic [24, 25, 31, 32] , functioning [28] and non-functioning [24, 27, 32] and metastatic and non-metastatic tumours [25, 29, 33] . In particular, 18 F-DOPA PET and PET/CT seem to be the most sensitive imaging methods for detecting head and neck PG, usually parasympathetic ganglia-derived tumours, probably due to the high tracer avidity of these neoplasms and the favourable lesion to background ratio in the head and neck [5] .
Furthermore, 18 F-DOPA PET and PET/CT seem to be accurate methods in both sporadic and inherited PG [28, 31] , except in SDHB-related PG [29] .
Finally, based on its high sensitivity and specificity, 18 F-DOPA PET may be considered the first-line tracer in the diagnostic workup of PG. Currently, the literature focusing on the use of 18 F-DOPA PET or PET/CT in PG remains limited; thus, further large multicentre studies will be necessary to substantiate the diagnostic accuracy of 18 F-DOPA PET and PET/CT in patients with PG.
Conclusion
In patients with suspected PG 18 F-DOPA PET and PET/CT demonstrated high sensitivity and specificity. 18 F-DOPA PET and PET/CT are accurate methods in this setting, but possible sources of false-negative results should be kept in mind. In particular, SDHB gene mutations could influence 18 F-DOPA PET or PET/CT diagnostic performance. Multicentre studies could substantiate the diagnostic accuracy of 18 F-DOPA PET and PET/CT in patients with PG.
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